Tag Archives: Yaron Werber

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE), Matinas BioPharma (NYSE MKT: MTNB) and ESSA Pharma Inc (NASDAQ: EPIX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ultragenyx Pharmaceutical, Inc. (RARE – Research Report), Matinas BioPharma (MTNB – Research Report) and ESSA Pharma Inc (EPIX – Research Report) with

Stoke Therapeutics Inc (STOK) Receives a Buy from Cowen & Co.

Cowen & Co. analyst Yaron Werber maintained a Buy rating on Stoke Therapeutics Inc (STOK – Research Report) yesterday. The company’s shares closed last Monday at $30.27, close to its 52-week high of $31.76. According to TipRanks.com, Werber is a

Cowen & Co. Keeps Their Buy Rating on BeiGene Ltd (BGNE)

In a report released today, Yaron Werber from Cowen & Co. maintained a Buy rating on BeiGene Ltd (BGNE – Research Report), with a price target of $170. The company’s shares closed yesterday at $133.48. According to TipRanks.com, Werber is

Cowen & Co. Reaffirms Their Hold Rating on Celgene (CELG)

Cowen & Co. analyst Yaron Werber maintained a Hold rating on Celgene (CELG – Research Report) today and set a price target of $102. The company’s shares opened today at $92.82, close to its 52-week high of $98.97. According to

Wave Life Sciences (WVE) Gets a Hold Rating from Cowen & Co.

Cowen & Co. analyst Yaron Werber maintained a Hold rating on Wave Life Sciences (WVE – Research Report) today. The company’s shares closed yesterday at $19.35, close to its 52-week low of $19.06. According to TipRanks.com, Werber is a 4-star

Regeneron (REGN) Gets a Hold Rating from Cowen & Co.

Cowen & Co. analyst Yaron Werber maintained a Hold rating on Regeneron (REGN – Research Report) today and set a price target of $353. The company’s shares closed on Friday at $309.18, close to its 52-week low of $287.66. According